Superworth

Protagonist Therapeutics PE ratio PTGX

Share price divided by earnings per share over the last twelve months, since 2024.

Today, Nov 2, 2026
135×
2-year median
60.1×
Against its 2-year history
81st
percentile: 0 is its lowest day, 100 its highest
2-year range
8.9× to 154×
Peer median
67.7×

Protagonist Therapeutics' PE ratio is 135× as of Nov 2, 2026: a share price of $139.37 against $1.03 of earnings per share over the last twelve months.

That is above its 2-year median of 60.1×, higher than on 81% of days in the last 2 years.

Over that time it ranged from 8.9× in Feb 2025 to 154× in Dec 2025.

The median for 10 large drugmakers of a similar size is 67.7×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far135×125×151×
2025143×8.9×154×
202414.6×11.5×18.0×

Against its peers

Companies in Drug Manufacturers - General nearest Protagonist Therapeutics' size, closest first, today.

Where Protagonist Therapeutics ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Protagonist Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.